Semaglutide 8mg in the Wegovy dose schedule: what this step means

Step 1: where the misconception about 8mg semaglutide usually comes from

Semaglutide exists in two completely separate product families. Rybelsus (an oral tablet for type 2 diabetes) comes in 3mg, 7mg, and 8mg strengths. That 8mg tablet is widely prescribed for blood-sugar control. Wegovy (the injectable and, since June 2026, the oral tablet licensed for weight management) follows an entirely different dose ladder. The two products share an active ingredient but serve different clinical purposes, carry different licences, and are titrated to different maintenance doses.

When 8mg semaglutide appears in weight-loss discussions, it is almost always a slip from the diabetes context. The NHS semaglutide medicines page sets out both product families clearly, which is a useful reference if you want to check exactly which form applies to your situation. The short answer: if your goal is weight management, the relevant dose ladder is the Wegovy one, and 8mg does not appear on it.

That said, the question is a reasonable one. Dosing language around GLP-1 medicines can feel confusing when so many strengths exist across so many products, and it is also worth being aware that semaglutide is not appropriate for everyone, including people with Prader-Willi syndrome, which is another reason a prescriber's job is partly to make sense of all of this for each individual patient.

Step 2: how the licensed Wegovy injection schedule is structured

Wegovy injections begin at 0.25mg once a week. That starting dose exists to let your body adjust, it is not intended to produce weight loss on its own. Nausea and other gastrointestinal effects are most common early in treatment, and the slow start substantially reduces their intensity for most people.

From there, a prescriber typically steps the dose up every four weeks: 0.25mg to 0.5mg, then 1.0mg, then 1.7mg, reaching the 2.4mg maintenance dose at around week 16. If you are curious about what the 1mg semaglutide dose involves and how it fits into the titration journey, that detail is covered separately. The MHRA approved a 7.2mg dose (initially via three 2.4mg pens per week, and from April 2026 as a dedicated single-dose pen) for adults whose BMI is 30 or above. You can read more about the full Wegovy treatment picture on the Wegovy overview page.

Titration is not automatic. A prescriber reviews how things are going at each step. If side effects are still settling, the step may be delayed. The goal is the highest dose a person tolerates well, which is not always the maximum. That decision belongs with the clinician, not a schedule on paper.

Step 3: what to expect as doses increase toward maintenance

Each dose step tends to bring a short period of adjustment. Nausea is the most commonly reported effect; constipation, loose stools, and reflux also feature for some people, particularly in the first week or two after a step up. For most, these effects settle. The NICE appraisal of semaglutide (TA875) summarises the clinical evidence base, including the tolerability profile observed across the STEP trials.

Weight loss tends to build gradually over the course of treatment. The clinical trial results at 2.4mg showed an average reduction of around 15% of body weight at 68 weeks, measured against a placebo group who also received lifestyle support. The newer 7.2mg data suggests a larger average reduction (around 20.7%) narrowing the gap with tirzepatide. These are trial averages; individual results vary considerably, and what happens at the 2mg semaglutide stage is worth understanding as part of that broader picture.

Stopping semaglutide abruptly is not recommended without speaking to your prescriber first. If a dose is missed, the patient information leaflet and your clinical team are the right guides on what to do next. Semaglutide is a prescription-only medicine, and all dose decisions (whether stepping up, pausing, or switching) require clinical oversight. If you are wondering whether Wegovy might suit your circumstances, the free consultation at nume is where that conversation starts: a real prescriber reviews your answers the same day.

What about the oral semaglutide tablet for weight loss?

One detail worth knowing, since it adds another layer to the dose-naming picture: the Wegovy tablet approved for weight management in the UK in June 2026 has its own schedule, 1.5mg, 4mg, 9mg, and 25mg. None of those overlap with the Rybelsus diabetes tablet strengths of 3mg, 7mg, and 8mg. So the 8mg tablet you may have encountered is firmly in the Rybelsus/diabetes lane, not the Wegovy weight-loss tablet lane.

The oral Wegovy tablet is taken first thing in the morning, before food, with a small amount of plain water, and the 25mg maintenance dose showed an average weight loss of around 13.6% over 64 weeks in the OASIS 4 trial. It requires no refrigeration, which some people find easier than managing an injectable pen. For more on how the injectable and tablet formats compare, the Wegovy page covers both in more detail.

Semaglutide in all its forms is a prescription-only medicine in the UK. Whether the injection or the tablet is the better fit depends on clinical history, lifestyle, and what a prescriber concludes after a proper assessment, not on which dose number sounds most familiar. Our clinical team reviews every consultation personally, and frequently asked questions about the process are answered on the FAQs page if you want a sense of what to expect before you begin.